Table 2

Controlled trials to study the remyelinating effects of IVIg in multiple sclerosis

	Noseworthy et al ¹⁸	Stangel et al ¹⁹	Noseworthy et al .²⁰
None of the outcome parameters were statistically significant.				EDSS, Expanded disability status scale; FS, functional systems score; FIM, functional independence measure; 9HPT, nine hole peg test; BBT, box and blocks test; SNRS, Scripps neurological rating scale; AI, abulation index; VER, visually evoked responses.
Design	Parallel	Modified cross over	Parallel
Patients included	67	10	55
Primary outcome	Targeted neurological deficit	Central conduction velocity	Change in log MAR scores
Secondary outcome	EDSS, FS, FIM, 9HPT, BBT	EDSS, SNRS, time to walk 20 m, manual muscle testing	EDSS, AI, FS, VER, visual fields, visual acuity, measures of disease activity
Dosage/time	0.4 g/kg for 5 days, then every 2 weeks for 3 months (total 11 infusions), evaluation after 6 months	0.4 g/kg for 5 days (total 5 infusions), evaluation 6 weeks later	0.4 g/kg for 5 days, then every 4 weeks for 3 months (total 8 infusions), evaluation after 6 months